药剂师领导的型肝炎诊断和快速管理 - 在社区 (PHARM-C):来自第四阶段非盲目的随机对照试验的结果
Mia J Biondi1,2, Camelia I Capraru2, Ben Harper3
1School of Nursing, York University, Toronto, Ontario, Canada.
Journal of viral hepatitis
|November 27, 2025
概括
药剂师主导的型肝炎病毒 (HCV) 治疗在社区试验中显示出可行性问题. 需要进一步的研究,以优化药剂师主导的护理模式,用于HCV管理.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 传染性疾病 传染性疾病
- 临床药房 临床药房
背景情况:
- 肝炎C病毒 (HCV) 感染需要可获得的治疗选择.
- 基于社区的护理模式可以改善患者获得医疗保健服务的机会.
研究的目的:
- 为了比较社区中药剂师主导的HCV治疗与传统的三级医疗保健的有效性.
- 识别基于社区的药剂师领导的HCV治疗试验所带来的挑战和经验教训.
主要方法:
- 进行了一项非盲目的随机对照试验.
- 参与者接受了由社区环境中的药剂师或第三级护理中的肝病学家领导的HCV治疗.
- 在药房环境中进行了HCV RNA测试.
主要成果:
- 该研究在15个月内招募了11名参与者,并因可行性问题而提前终止.
- 在34名抗体阳性个体中,28人在药房完成了HCVRNA快速检测.
- 招聘持续了大约27个月.
结论:
- 在社区中由药剂师领导的HCV治疗面临可行性挑战.
- 关于实施此类模型的重要经验教训.
- 未来的努力需要仔细考虑这些教训,以获得成功的社区 HCV 管理.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
203
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
203
Pulmonary Tuberculosis V
527
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
527
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
196
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
196


